In vivo evaluation of novel particle‐free polycaprolactone fillers for safety, degradation, and neocollagenesis in a rat model

2021 ◽  
Author(s):  
Ji Yeon Hong ◽  
Jong Hwan Kim ◽  
Tae‐Rin Kwon ◽  
Jun Ki Hong ◽  
Kapsok Li ◽  
...  
Keyword(s):  
Rat Model ◽  
In Vivo Evaluation

scholarly journals A New Symmetrical Thiazolidinedione Derivative: In Silico Design, Synthesis, and In Vivo Evaluation on a Streptozotocin- Induced Rat Model of Diabetes

Processes ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 1294
Author(s):  
Samuel Álvarez-Almazán ◽  
Gabriel Navarrete-Vázquez ◽  
Itzia Irene Padilla-Martínez ◽  
José Correa-Basurto ◽  
Diana Alemán-González-Duhart ◽  
...  
Keyword(s):  
Rat Model ◽  
In Silico ◽  
Female Rats ◽  
Therapeutic Effects ◽  
Acute Oral Toxicity ◽  
Oral Toxicity ◽  
In Vivo Evaluation ◽  
Docking Simulations ◽  
Ppar Γ

By activating PPAR-γ, thiazolidinediones normalize glucose levels in animal models of type 2 diabetes and in patients with this pathology. The aim of the present study was to analyze 219 new derivatives in silico and select the best for synthesis, to be evaluated for acute oral toxicity in female rats and for control of diabetes-related parameters in a rat model of streptozotocin-induced diabetes. The best compound was chosen based on pharmacokinetic, pharmacodynamic, and toxicological parameters obtained in silico and binding orientation observed by docking simulations on PPAR-γ. Compound 1G was synthesized by a quick and easy Knoevenagel condensation. Acute oral toxicity was found at a dose greater than 2000 mg/Kg. Compound 1G apparently produces therapeutic effects similar to those of pioglitazone, decreasing glycaemia and triglyceride levels in diabetic animals, without liver damage. Moreover, it did not cause a significant weight gain and tended to reduce polydipsia and polyphagia, while diminishing systemic inflammation related to TNF-α and IL-6. It lowered the level of endogenous antioxidant molecules such as reduced glutathione and glutathione reductase. In conclusion, 1G may be a candidate for further testing as an euglycemic agent capable of preventing the complications of diabetes.

scholarly journals Antihyperuricemic, Anti-Inflammatory and Antihypertensive Effect of a Dry Extract from Solidago virgaurea L. (Asteraceae)

2021 ◽  
Vol 89 (2) ◽  
pp. 27
Author(s):  
Mircea Tămaş ◽  
Oliviu Vostinaru ◽  
Loredana Soran ◽  
Ildiko Lung ◽  
Ocsana Opris ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Rat Model ◽  
Antihypertensive Effect ◽  
Chemical Constituents ◽  
In Vivo Evaluation ◽  
Dry Extract ◽  
The Balkans ◽  
Solidago Virgaurea ◽  
Anti Inflammatory

Solidago virgaurea L. is a perennial plant used in European traditional medicine as a diuretic or a remedy for inflammatory conditions of the urinary tract but also for gout, especially in the Balkans. The present study was focused on a preclinical, in vivo evaluation of antihyperuricemic, anti-inflammatory, and antihypertensive effects of a dry extract from S. virgaurea L. (ESV). Colorimetric and HPLC–MS techniques were used to identify the main chemical constituents of ESV. Antihyperuricemic effect of ESV was assessed in a rat model of hyperuricemia induced by the administration of potassium oxonate. Antihypertensive effect of ESV was evaluated in hyperuricemic rats by monitoring systolic blood pressure with a non-invasive blood-pressure recording system. The anti-inflammatory effect of ESV was tested using a rat model of paw edema. The main chemical constituents of ESV were rutin and phenolic acids represented by chlorogenic and caffeic acid. ESV demonstrated significant antihyperuricemic effects in rats due to an uricosuric mechanism. Additionally, ESV reduced the progression of arterial hypertension in hyperuricemic rats and also showed anti-inflammatory properties slightly inferior to diclofenac. The results suggest that ESV could be a natural remedy for the treatment of gout and protection against endothelial dysfunction caused by hyperuricemia.

.alpha.-Methylproline-containing renin inhibitory peptides: in vivo evaluation in an anesthetized, ganglion-blocked, hog renin infused rat model

1987 ◽  
Vol 30 (3) ◽  
pp. 536-541 ◽  
Author(s):  
Suvit Thaisrivongs ◽  
Donald T. Pals ◽  
Judy A. Lawson ◽  
Steve R. Turner ◽  
Douglas W. Harris
Keyword(s):  
Rat Model ◽  
In Vivo Evaluation ◽  
Inhibitory Peptides

scholarly journals Development of non-invasive Raman spectroscopy for in vivo evaluation of bone graft osseointegration in a rat model

The Analyst ◽  
2010 ◽  
Vol 135 (12) ◽  
pp. 3142 ◽  
Author(s):  
Paul I. Okagbare ◽  
Francis W. L. Esmonde-White ◽  
Steven A. Goldstein ◽  
Michael D. Morris
Keyword(s):  
Raman Spectroscopy ◽  
Bone Graft ◽  
Rat Model ◽  
In Vivo Evaluation ◽  
Non Invasive

In vivo Evaluation Method of the Effect of Nattokinase on Carrageenan-Induced Tail Thrombosis in a Rat Model

2010 ◽  
Vol 124 (4) ◽  
pp. 218-224 ◽  
Author(s):  
Seitaro Kamiya ◽  
Masayori Hagimori ◽  
Masayoshi Ogasawara ◽  
Masayuki Arakawa
Keyword(s):  
Rat Model ◽  
Evaluation Method ◽  
In Vivo Evaluation

scholarly journals In vivo evaluation of drug dialyzability in a rat model of hemodialysis

PLoS ONE ◽  
2020 ◽  
Vol 15 (6) ◽  
pp. e0233925
Author(s):  
Masaki Fukunaga ◽  
Daisuke Kadowaki ◽  
Mika Mori ◽  
Satomi Hagiwara ◽  
Yuki Narita ◽  
...  
Keyword(s):  
Rat Model ◽  
In Vivo Evaluation

scholarly journals The Effect of Sertoli Cells on Xenotransplantation and Allotransplantation of Ventral Mesencephalic Tissue in a Rat Model of Parkinson’s Disease

Cells ◽  
2019 ◽  
Vol 8 (11) ◽  
pp. 1420
Author(s):  
Yun-Ting Jhao ◽  
Chuang-Hsin Chiu ◽  
Chien-Fu F. Chen ◽  
Ta-Kai Chou ◽  
Yi-Wen Lin ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Rat Model ◽  
Sertoli Cells ◽  
Dopaminergic Neurons ◽  
Sprague Dawley ◽  
Drug Induced ◽  
In Vivo Evaluation ◽  
Ventral Mesencephalic

Intra-striatal transplantation of fetal ventral mesencephalic (VM) tissue has a therapeutic effect on patients with Parkinson’s disease (PD). Sertoli cells (SCs) possess immune-modulatory properties that benefit transplantation. We hypothesized that co-graft of SCs with VM tissue can attenuate rejection. Hemi-parkinsonian rats were generated by injecting 6-hydroxydopamine into the right medial forebrain bundle of Sprague Dawley (SD) rats. The rats were then intrastriatally transplanted with VM tissue from rats or pigs (rVM or pVM), with/without a co-graft of SCs (rVM+SCs or pVM+SCs). Recovery of dopaminergic function and survival of the grafts were evaluated using the apomorphine-induced rotation test and small animal-positron emission tomography (PET) coupled with [18F] DOPA or [18F] FE-PE2I, respectively. Immunohistochemistry (IHC) examination was used to determine the survival of the grafted dopaminergic neurons in the striatum and to investigate immune-modulatory effects of SCs. The results showed that the rVM+SCs and pVM+SCs groups had significantly improved drug-induced rotational behavior compared with the VM alone groups. PET revealed a significant increase in specific uptake ratios (SURs) of [18F] DOPA and [18F] FE-PE2I in the grafted striatum of the rVM+SCs and pVM+SCs groups as compared to that of the rVM and pVM groups. SC and VM tissue co-graft led to better dopaminergic (DA) cell survival. The co-grafted groups exhibited lower populations of T-cells and activated microglia compared to the groups without SCs. Our results suggest that co-graft of SCs benefit both xeno- and allo-transplantation of VM tissue in a PD rat model. Use of SCs enhanced the survival of the grafted dopaminergic neurons and improved functional recovery. The enhancement may in part be attributable to the immune-modulatory properties of SCs. In addition, [18F]DOPA and [18F]FE-PE2I coupled with PET may provide a feasible method for in vivo evaluation of the functional integrity of the grafted DA cell in parkinsonian rats.

Sign in / Sign up

Export Citation Format

Share Document